Marker May Predict Immunotherapy Benefit in High-Risk Neuroblastoma – Cancer Network
|
Marker May Predict Immunotherapy Benefit in High-Risk Neuroblastoma
Cancer Network Previous data from a phase III clinical trial involving 226 high-risk neuroblastoma patients showed that isotretinoin plus the immunotherapy regimen of dinutuximab, sargramostim, and aldesleukin significantly improved event-free and overall survival vs … |
